KRYSNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Krystal Biotech, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$320.25+3.67 (+1.16%)
Close on Oct 19, 2026
- Market cap
- $9.82B
- P/E (TTM)
- 40.1
- Dividend yield
- –
Share price
+$130.02 (+68.35%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Krystal Biotech, Inc. grew revenue 22.6% to $440.48M over the twelve months to Jun 30, 2026. Operating income rose 41.8% to $197.75M, moving the operating margin from 38.8% to 44.9%. Free cash flow was $257.78M, up 39.0% from a year earlier.
Revenue
$440.48M
+22.6% vs. a year earlier
Operating income
$197.75M
+41.8% vs. a year earlier
Free cash flow
$257.78M
+39.0% vs. a year earlier
EPS, diluted
$7.98
+62.2% vs. a year earlier
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $9.82B
- P/E ratio
- 40.1
- Price to sales
- 22.29
- Price to book
- 7.22
- Dividend yield
- –
- Free cash flow yield
- 2.63%
Fundamentals
- Revenue
- $440.48M
- Net income
- $241.47M
- EPS, diluted
- $7.98
- Free cash flow
- $257.78M
- Book value per share
- $44.33
- Diluted shares
- 31M
Ten years at a glance
Fiscal years 2016 to 2025 and trailing twelve months, USD
Revenue
$440.48M+22.6% YoY
Operating income
$197.75M+41.8% YoY
Net income
$241.47M+64.6% YoY
EPS, diluted
$7.98+62.2% YoY
Free cash flow
$257.78M+39.0% YoY
Reported periodTrailing twelve months